Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections
- PMID: 27093979
- PMCID: PMC5214718
- DOI: 10.3904/kjim.2015.113
Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections
Abstract
Background/aims: Although multidrug resistance (MDR) among extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) poses significant therapeutic challenges, little is known regarding the risk factors and epidemiology of community-onset MDR-ESBL-EC infections. We performed this study to investigate risk factors and the molecular epidemiology of community-onset MDR-ESBL-EC infections.
Methods: We conducted a case-control-control study of community-onset infections. MDR-ESBL-EC was defined as ESBL-EC that demonstrated in vitro resistance to trimethoprim-sulfamethoxazole, fluoroquinolones (FQs), and gentamicin. Patients with MDR-ESBL-EC infections were designated as case patients. A control group I (CG I) patient was defined as a person whose clinical sample yielded ESBL-EC that did not meet the criteria for MDR. A control group II (CG II) patient was defined as a patient with a non-ESBL-EC infection.
Results: Of 108 patients with ESBL-EC infections, 30 cases (27.8%) were due to MDR-ESBL-EC. Compared with CG I, prior use of FQs (odds ratio [OR], 3.16; 95% confidence interval [CI], 1.11 to 8.98) and immunosuppressant use (OR, 10.47; 95% CI, 1.07 to 102.57) were significantly associated with MDR-ESBL-EC. Compared with CG II, prior use of FQs (OR, 15.53; 95% CI, 2.86 to 84.27) and healthcare-associated infection (OR, 5.98; 95% CI, 2.26 to 15.86) were significantly associated with MDR-ESBL-EC. CTX-M-15 was the most common in MDR-ESBL-EC infections (59.1% [13/22]), while CTX-M-14 was the most common in non-MDR-ESBL-EC infections (41.6% [32/77]). CTX-M-15 was significantly associated with MDR-ESBL-EC (59.1% vs. 32.5%, p = 0.028). Pulsed-field gel electrophoresis showed clonal diversity of MDR-ESBL-EC isolates.
Conclusions: The emergence of strains of MDR-ESBL-EC in the community poses an important new public health threat. More information on the emergence and transmission of these strains will be necessary in order to prevent their spread.
Keywords: Community-onset infection; Drug resistance, multiple; Escherichia coli; Extended-spectrum β-lactamase.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures

Similar articles
-
Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.Am J Infect Control. 2007 Nov;35(9):606-12. doi: 10.1016/j.ajic.2007.05.008. Am J Infect Control. 2007. PMID: 17980240
-
Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.J Antimicrob Chemother. 2006 Apr;57(4):780-3. doi: 10.1093/jac/dkl035. Epub 2006 Feb 21. J Antimicrob Chemother. 2006. PMID: 16492721
-
Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.Microb Drug Resist. 2012 Oct;18(5):518-24. doi: 10.1089/mdr.2012.0067. Epub 2012 Jun 28. Microb Drug Resist. 2012. PMID: 22742454
-
Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact.Curr Opin Infect Dis. 2010 Aug;23(4):320-6. doi: 10.1097/qco.0b013e3283398dc1. Curr Opin Infect Dis. 2010. PMID: 20614578 Review.
-
Emerging threats: Antimicrobial resistance in extended-spectrum beta-lactamase and carbapenem-resistant Escherichia coli.Microb Pathog. 2025 Mar;200:107275. doi: 10.1016/j.micpath.2024.107275. Epub 2025 Jan 9. Microb Pathog. 2025. PMID: 39798725 Review.
Cited by
-
Trends in South Korean antimicrobial use and association with changes in Escherichia coli resistance rates: 12-year ecological study using a nationwide surveillance and antimicrobial prescription database.PLoS One. 2018 Dec 31;13(12):e0209580. doi: 10.1371/journal.pone.0209580. eCollection 2018. PLoS One. 2018. PMID: 30596704 Free PMC article.
-
Rapid and sensitive detection of Shigella flexneri using fluorescent microspheres as label for immunochromatographic test strip.Ann Transl Med. 2019 Oct;7(20):565. doi: 10.21037/atm.2019.09.46. Ann Transl Med. 2019. PMID: 31807546 Free PMC article.
-
Extended spectrum beta lactamase producing bacteria among outpatients with ear infection at FelegeHiwot Referral Hospital, North West Ethiopia.PLoS One. 2020 Sep 11;15(9):e0238891. doi: 10.1371/journal.pone.0238891. eCollection 2020. PLoS One. 2020. PMID: 32915859 Free PMC article.
-
Bloodstream Infections Caused by Multidrug Resistant Bacteria: Clinical and Microbiological Features and Mortality.Sisli Etfal Hastan Tip Bul. 2023 Sep 29;57(3):416-425. doi: 10.14744/SEMB.2023.31697. eCollection 2023. Sisli Etfal Hastan Tip Bul. 2023. PMID: 37900327 Free PMC article.
-
Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to 2016.Antimicrob Resist Infect Control. 2019 Aug 27;8:144. doi: 10.1186/s13756-019-0599-y. eCollection 2019. Antimicrob Resist Infect Control. 2019. PMID: 31467670 Free PMC article.
References
-
- Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004;140:26–32. - PubMed
-
- Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–166. - PubMed
-
- Rodriguez-Bano J, Picon E, Gijon P, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010;50:40–48. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical